12/3/2021, 1:14 PM (Source: TeleTrader)
more TeleTrader news

FDA to review jabs, drugs targeting Omicron variant

The United States Food and Drug Administration plans to start a rapid review of COVID-19 vaccines and other medicines that target the newly registered Omicron coronavirus variant in case that specific products are needed to fight this mutation, according to a report published by The Wall Street Journal on Friday.

The FDA has reportedly held meetings with vaccine and drug makers in order to establish guidelines so it can rapidly review studies and other data on their efficacy versus the Omicron variant. The new standards would work similarly to those that companies had to meet in order to receive the agency's approval for booster vaccine doses.

COVID-19 vaccines that specifically target the new coronavirus mutation can be produced in around three months, vaccine makers Pfizer and BioNTech previously estimated.

Baha Breaking the News (BBN) / ND